Advanced Utilization Management Program


National CooperativeRx constantly monitors the pharmaceutical marketplace for new therapies in the pipeline. We have implemented our opt-in Advanced Utilization Management program to offer our member groups an opportunity to employ our recommendations on a quarterly basis to better adapt their plans to the rapidly changing market. We are currently focusing on the management of the following categories.

Antichelation Medications for Wilsons’s Disease or cystinuria (Cuprimine, Depen only)

Target Drugs: trientine, Syprine, Clovique, Cuprimine, Depen


Target Drug: Prevymis

Continuous Blood Glucose Monitors (CGM), where covered

Target Drugs: Dexcom Receiver

Digestive Aids

Target Drug: Sucraid

New-to-Market Anti-Seizure Nasal Sprays (e.g. seizure rescue medications)

Target Drugs: Valtoco, Nayzliam

Oral Allergy Immunotherapy, where covered

Target Drugs: Grastek, Odactra, Oralair, Ragwitek, Palforzia

Oral Migraine

Target Drugs: Nurtec, Ubrelvy, Reyvow


Target Drugs: Sunosi, Xyrem

This page was last updated on April 23, 2021.